Top 5 Stocks to Buy Now
→ Why this tiny stock may move before the SpaceX IPO drops (From Behind the Markets) (Ad)tc pixel Free NCYT Stock Alerts

Novacyt (NCYT) Competitors

Novacyt logo
GBX 33 -0.90 (-2.65%)
As of 12:14 PM Eastern
Compare

NCYT vs. CREO, IUG, IHC, RUA, and AVO

Should you buy Novacyt stock or one of its competitors? MarketBeat compares Novacyt with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Novacyt include Creo Medical Group (CREO), Intelligent Ultrasound Group (IUG), Inspiration Healthcare Group (IHC), RUA Life Sciences (RUA), and Advanced Oncotherapy (AVO). These companies are all part of the "medical devices" industry.

How does Novacyt compare to Creo Medical Group?

Creo Medical Group (LON:CREO) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

Creo Medical Group has higher earnings, but lower revenue than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£6M10.93-£25.04M£1.0013.50
Novacyt£20.03M1.19-£36.80M-£32.00N/A

Creo Medical Group has a beta of 1.6246382, suggesting that its stock price is 62% more volatile than the broader market. Comparatively, Novacyt has a beta of 1.105, suggesting that its stock price is 11% more volatile than the broader market.

In the previous week, Creo Medical Group's average media sentiment score of 0.00 equaled Novacyt'saverage media sentiment score.

Company Overall Sentiment
Creo Medical Group Neutral
Novacyt Neutral

44.1% of Creo Medical Group shares are owned by institutional investors. Comparatively, 10.7% of Novacyt shares are owned by institutional investors. 6.4% of Creo Medical Group shares are owned by company insiders. Comparatively, 0.7% of Novacyt shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Creo Medical Group has a net margin of 88.33% compared to Novacyt's net margin of -135.96%. Creo Medical Group's return on equity of 9.56% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group88.33% 9.56% -20.09%
Novacyt -135.96%-121.30%-27.98%

Summary

Creo Medical Group beats Novacyt on 10 of the 11 factors compared between the two stocks.

How does Novacyt compare to Intelligent Ultrasound Group?

Novacyt (LON:NCYT) and Intelligent Ultrasound Group (LON:IUG) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

In the previous week, Novacyt's average media sentiment score of 0.00 equaled Intelligent Ultrasound Group'saverage media sentiment score.

Company Overall Sentiment
Novacyt Neutral
Intelligent Ultrasound Group Neutral

Intelligent Ultrasound Group has lower revenue, but higher earnings than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than Intelligent Ultrasound Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novacyt£20.03M1.19-£36.80M-£32.00N/A
Intelligent Ultrasound Group£6.57M0.00-£2.27M-£0.68N/A

10.7% of Novacyt shares are owned by institutional investors. Comparatively, 75.5% of Intelligent Ultrasound Group shares are owned by institutional investors. 0.7% of Novacyt shares are owned by company insiders. Comparatively, 12.8% of Intelligent Ultrasound Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Intelligent Ultrasound Group has a net margin of -23.11% compared to Novacyt's net margin of -135.96%. Intelligent Ultrasound Group's return on equity of -23.58% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Novacyt-135.96% -121.30% -27.98%
Intelligent Ultrasound Group -23.11%-23.58%-13.51%

Novacyt has a beta of 1.105, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Intelligent Ultrasound Group has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Summary

Intelligent Ultrasound Group beats Novacyt on 7 of the 10 factors compared between the two stocks.

How does Novacyt compare to Inspiration Healthcare Group?

Novacyt (LON:NCYT) and Inspiration Healthcare Group (LON:IHC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Novacyt has a beta of 1.105, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Inspiration Healthcare Group has a beta of 0.867, meaning that its stock price is 13% less volatile than the broader market.

10.7% of Novacyt shares are owned by institutional investors. Comparatively, 7.4% of Inspiration Healthcare Group shares are owned by institutional investors. 0.7% of Novacyt shares are owned by company insiders. Comparatively, 8.4% of Inspiration Healthcare Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Inspiration Healthcare Group's average media sentiment score of 0.94 beat Novacyt's score of 0.00 indicating that Inspiration Healthcare Group is being referred to more favorably in the news media.

Company Overall Sentiment
Novacyt Neutral
Inspiration Healthcare Group Positive

Inspiration Healthcare Group has higher revenue and earnings than Novacyt. Inspiration Healthcare Group is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novacyt£20.03M1.19-£36.80M-£32.00N/A
Inspiration Healthcare Group£45.20M0.45-£12.20M-£13.65N/A

Inspiration Healthcare Group has a net margin of -2.19% compared to Novacyt's net margin of -135.96%. Inspiration Healthcare Group's return on equity of -6.49% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Novacyt-135.96% -121.30% -27.98%
Inspiration Healthcare Group -2.19%-6.49%-3.47%

Summary

Inspiration Healthcare Group beats Novacyt on 8 of the 12 factors compared between the two stocks.

How does Novacyt compare to RUA Life Sciences?

Novacyt (LON:NCYT) and RUA Life Sciences (LON:RUA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

RUA Life Sciences has lower revenue, but higher earnings than Novacyt.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novacyt£20.03M1.19-£36.80M-£32.00N/A
RUA Life Sciences£4.11M2.91-£2.66MN/AN/A

RUA Life Sciences has a net margin of -3.26% compared to Novacyt's net margin of -135.96%. RUA Life Sciences' return on equity of -2.03% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Novacyt-135.96% -121.30% -27.98%
RUA Life Sciences -3.26%-2.03%-17.50%

In the previous week, Novacyt's average media sentiment score of 0.00 equaled RUA Life Sciences'average media sentiment score.

Company Overall Sentiment
Novacyt Neutral
RUA Life Sciences Neutral

Novacyt has a beta of 1.105, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, RUA Life Sciences has a beta of 0.958, suggesting that its stock price is 4% less volatile than the broader market.

10.7% of Novacyt shares are owned by institutional investors. Comparatively, 0.1% of RUA Life Sciences shares are owned by institutional investors. 0.7% of Novacyt shares are owned by company insiders. Comparatively, 7.3% of RUA Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

RUA Life Sciences beats Novacyt on 6 of the 10 factors compared between the two stocks.

How does Novacyt compare to Advanced Oncotherapy?

Advanced Oncotherapy (LON:AVO) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

In the previous week, Advanced Oncotherapy's average media sentiment score of 0.00 equaled Novacyt'saverage media sentiment score.

Company Overall Sentiment
Advanced Oncotherapy Neutral
Novacyt Neutral

Advanced Oncotherapy has a net margin of 0.00% compared to Novacyt's net margin of -135.96%. Advanced Oncotherapy's return on equity of -67.34% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Advanced OncotherapyN/A -67.34% -11.73%
Novacyt -135.96%-121.30%-27.98%

17.8% of Advanced Oncotherapy shares are owned by institutional investors. Comparatively, 10.7% of Novacyt shares are owned by institutional investors. 47.5% of Advanced Oncotherapy shares are owned by insiders. Comparatively, 0.7% of Novacyt shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Advanced Oncotherapy has a beta of 0.06, meaning that its share price is 94% less volatile than the broader market. Comparatively, Novacyt has a beta of 1.105, meaning that its share price is 11% more volatile than the broader market.

Advanced Oncotherapy has higher earnings, but lower revenue than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than Advanced Oncotherapy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Advanced OncotherapyN/AN/A-£32.60M-£0.07N/A
Novacyt£20.03M1.19-£36.80M-£32.00N/A

Summary

Advanced Oncotherapy beats Novacyt on 7 of the 10 factors compared between the two stocks.

Get Novacyt News Delivered to You Automatically

Sign up to receive the latest news and ratings for NCYT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NCYT vs. The Competition

Export
MetricNovacytMedical Devices IndustryMedical SectorLON Exchange
Market Cap£23.91M£2.10B£6.47B£2.78B
Dividend YieldN/A2.67%2.68%6.16%
P/E Ratio-1.0314.6124.71365.72
Price / Sales1.19123.83521.5186,253.69
Price / Cash0.5815.9927.9227.85
Price / Book0.334.4110.827.92
Net Income-£36.80M£144.75M£3.56B£5.89B
7 Day Performance-5.17%-0.74%1.67%-0.87%
1 Month Performance-33.73%-2.44%0.43%-0.76%
1 Year Performance-21.00%-2.56%32.84%70.67%

Novacyt Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NCYT
Novacyt
N/AGBX 33
-2.7%		N/A-21.2%£23.91M£20.03MN/A120
CREO
Creo Medical Group
N/AGBX 13.75
flat		GBX 40
+190.9%		-7.1%£66.80M£6M13.75279
IUG
Intelligent Ultrasound Group
N/AN/AN/AN/A£42.76M£6.57MN/A65
IHC
Inspiration Healthcare Group
N/AGBX 26
flat		N/A-3.0%£23.31M£45.20MN/A224
RUA
RUA Life Sciences
N/AGBX 18.98
-2.7%		N/A+38.6%£12.10M£4.11MN/A48

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:NCYT) was last updated on 6/23/2026 by MarketBeat.com Staff.
From Our Partners
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel